Moreover, combination of drugs with different phase specific cytotoxicities such as combination of p19 and p53 gene therapy, where p19 is important to inactivate p53 inhibitors and p53 itself triggers apoptosis, appear promising to target gliomas. This evidence concerns the gene CDKN2A and central nervous system cancer.